Katherine N. Weilbaecher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Katherine N. Weilbaecher has a total of 334 co-authors. Here are the top co-authors by number of shared publications:
- Foluso Olabisi Ademuyiwa
Department of Medicine, Washington University in St Louis, St Louis, Mo
57 shared publications - Andrew A. Davis
Division of Oncology, Washington University in St. Louis, St. Louis, MO, United States
49 shared publications - Ashley Frith
Department of Medicine Division of Oncology Washington University School of Medicine in St. Louis MO
49 shared publications - Caron Rigden
Department of Medicine Division of Oncology Washington University School of Medicine in St. Louis MO
49 shared publications - Cynthia X. Ma
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, USA
49 shared publications - Katherine Clifton
Division of Oncology, Department of Medicine, Washington University in Saint Louis School of Medicine, Saint Louis, USA
49 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Elsevier in Journal of Bone Oncology
- Vol. 58
CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy
- 25 April 2026
- Published by Elsevier in Journal of Bone Oncology
- Vol. 58
Open AccessCDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S10 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Contains supplemental figures and legends
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy
Table containing all of our reagents
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Gene alterations associated with shorter PFS.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Gene alterations associated with shorter PFS.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Supplementary Figure S1. High bTMB is associated with the presence of specific mutations.Supplementary Figure S2. ROC analysis to determine optimal bTMB cutoff.Supplementary Figure S3. High correlation between bTMB determined from WES and a 152-gene targeted sequencing panel.Supplementary Figure S4. Association between high cfDNA yield and shorter PFS.Supplementary Figure S5. High baseline tumor fraction is associated with shorter PFS.Supplementary Figure S6. bTMB scores are not associated with sites of metastatic spread.Supplementary Figure S7. Specific oncogenic signaling pathways are more frequently altered inpatients with high bTMB and bCNB scores.Supplementary Figure S8. Genomic landscape of all patients at baseline.Supplementary Figure S9. bTMB and bCNB at baseline vs. progression.Supplementary Figure S10. Correlation between baseline bCNB and bTMB.Supplementary Figure S11. Comparison of ctDNA dynamics as measured by ctDNA fraction andbCNB during treatment and progression.Supplementary Figure S12. Genome-wide plots of copy number changes across treatment timepoints.Supplementary Figure S13. Copy number changes detected for RB1 and BRCA2 genes acrosstreatment time points.Supplementary Figure S14. Relationship between ctDNA fraction and bTMB and bCNBSupplementary Figure S15. Relationship between tumor fraction and bCNB.